Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML | Zendy

Alexander E. Perl | Zendy; Giovanni Martinelli | Zendy; Jorge E. Cortés | Zendy; Andreas Neubauer | Zendy; Ellin Berman | Zendy; Stefania Paolini | Zendy; Pau Montesinos | Zendy; Maria R. Baer | Zendy; Richard A. Larson | Zendy; Celalettin Üstün | Zendy; Francesco Fabbiano | Zendy; Harry P. Erba | Zendy; Antonio Di Stasi | Zendy; Robert K. Stuart | Zendy; Rebecca L. Olin | Zendy; Margaret Kasner | Zendy; Fabio Ciceri | Zendy; WenChien Chou | Zendy; Nikolai A. Podoltsev | Zendy; Christian Récher | Zendy; Hisayuki Yokoyama | Zendy; Naoko Hosono | Zendy; SungSoo Yoon | Zendy; JeHwan Lee | Zendy; Timothy S. Pardee | Zendy; Amir T. Fathi | Zendy; Chaofeng Liu | Zendy; Nahla Hasabou | Zendy; Xuan Liu | Zendy; Erkut Bahceci | Zendy; Mark J. Levis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Author(s) -

Alexander E. Perl,

Giovanni Martinelli,

Jorge E. Cortés,

Andreas Neubauer,

Ellin Berman,

Stefania Paolini,

Pau Montesinos,

Maria R. Baer,

Richard A. Larson,

Celalettin Üstün,

Francesco Fabbiano,

Harry P. Erba,

Antonio Di Stasi,

Robert K. Stuart,

Rebecca L. Olin,

Margaret Kasner,

Fabio Ciceri,

WenChien Chou,

Nikolai A. Podoltsev,

Christian Récher,

Hisayuki Yokoyama,

Naoko Hosono,

SungSoo Yoon,

JeHwan Lee,

Timothy S. Pardee,

Amir T. Fathi,

Chaofeng Liu,

Nahla Hasabou,

Xuan Liu,

Erkut Bahceci,

Mark J. Levis

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1902688

Subject(s) - medicine , refractory (planetary science) , hazard ratio , chemotherapy , surgery , salvage therapy , gastroenterology , confidence interval , biology , astrobiology

Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene ( FLT3 ) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3 -mutated AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research